A reversible inhibitor of monoamine oxidase A (RIMA) is a compound that binds the MAO-A enzyme through reversible, competitive inhibition, slowing the breakdown of serotonin, norepinephrine, and dopamine. The class is defined by a single pharmacological criterion — reversible MAO-A selectivity — which sharply distinguishes RIMAs from the older irreversible MAO inhibitors that permanently disable the enzyme.[1]
As covered here, the class spans plant-derived beta-carboline alkaloids and the preparations that contain them: harmine, harmaline, the Amazonian vine Banisteriopsis caapi, the Eurasian seed Peganum harmala (Syrian rue), and the ayahuasca brew. These members differ in alkaloid ratio, preparation, and cultural setting, but converge on the same enzymatic action through a shared tricyclic beta-carboline scaffold.[2]
At low exposures, RIMAs produce mild monoamine-elevation effects — modestly increased alertness and mood elevation — and in pharmaceutical members deliver antidepressant activity comparable to tricyclics with better tolerability.[3] In plant-derived form they appear in ceremonial preparations where they enable oral activity of co-administered DMT, and at higher exposures the beta-carbolines themselves can produce visionary, dream-like, or tremulous states.[4]
Pharmacology
Most plant-derived RIMAs reach the same endpoint — elevated synaptic serotonin, norepinephrine, and dopamine — through reversible competitive binding of beta-carboline alkaloids to the MAO-A active site, where they engage the enzyme's flavin cofactor without forming a covalent bond.[2]
| Constituent | Representative source | How it reaches the shared endpoint |
|---|---|---|
| Harmine | B. caapi, P. harmala | Most potent MAO-A inhibitor among the beta-carbolines; binds reversibly at the flavin-cofactor active site[2] |
| Harmaline | P. harmala, B. caapi | Reversible competitive MAO-A inhibition; less potent than harmine, with additional olivocerebellar activity at high exposure[4] |
| Whole-plant alkaloid mixtures | P. harmala seed, ayahuasca brew | Deliver harmine, harmaline, and co-occurring alkaloids in orally bioavailable form[5] |
The mechanistic detail matters less for safety than the shared endpoint: raised monoamine tone — and reduced tyramine clearance — across the body and CNS. Reversibility is the safety-relevant property of the class. Because beta-carbolines bind non-covalently, rising substrate or tyramine concentrations can partially displace them from MAO-A, allowing some enzyme activity to resume.[6] Enzyme function typically returns within roughly a day after a dose clears, in contrast to the multi-week recovery required after irreversible MAOIs.[7]
A co-occurring beta-carboline in B. caapi and ayahuasca, tetrahydroharmine, is not itself a RIMA — it acts as a weak serotonin reuptake inhibitor and contributes to the serotonergic load of those preparations without sharing the class's defining mechanism.[8]
Substances
The class is illustrated by members spanning isolated alkaloids, source plants, and a preparation:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Harmine | Isolated beta-carboline alkaloid | Most potent MAO-A inhibitor in the group; the reference compound in beta-carboline pharmacology |
| Harmaline | Isolated beta-carboline alkaloid | Less potent at MAO-A, but distinguished by dose-dependent tremor through an olivocerebellar mechanism |
| Banisteriopsis caapi | Source plant (Amazonian vine) | Stem bark carries harmine, harmaline, and tetrahydroharmine; the RIMA component of ayahuasca |
| Peganum harmala | Source plant (Eurasian seed) | Alkaloid-rich seeds used as a standalone, high-concentration natural RIMA source |
| Ayahuasca | Plant preparation | Decoction in which beta-carboline RIMA activity enables oral activity of a co-administered DMT plant |
These members differ in chemistry of preparation, alkaloid ratio, and cultural setting, but each delivers reversible MAO-A inhibition as its pharmacological core.
Subjective Effects
At qualitatively low exposures, RIMA activity registers mainly as monoamine-elevation effects: mild alertness, modest mood lift, and in some contexts a faint perceptual brightening reflecting raised serotonergic and noradrenergic tone.[9] At higher exposures, the beta-carbolines themselves contribute subjectively distinct states.
| Exposure | Characteristic effects |
|---|---|
| Low | Modest alertness, mild mood elevation, faint perceptual enhancement |
| Moderate–high | Nausea, dream-like or visionary imagery (especially with harmaline-dominant preparations), emotional lability |
| High | Whole-body tremor (particularly harmaline), dysphoria, marked autonomic activation |
The same monoaminergic axis that drives the sought effects also drives the class's defining acute risks — as exposure rises, the buffer between desired and adverse effects narrows, and any concurrent serotonergic agent further compresses that margin.
In the ayahuasca context, the experiential profile is primarily shaped by DMT rather than by the RIMA component, with the beta-carbolines modulating DMT's bioavailability and contributing their own monoaminergic colouring.[8]
Safety
Risk profile
The defining acute danger of this class is serotonin toxicity (serotonin syndrome) when combined with other serotonergic agents — SSRIs, SNRIs, tramadol, pethidine/meperidine, triptans, linezolid, MDMA, and other compounds that raise synaptic serotonin. Reversible MAO-A inhibition adds to whatever serotonergic load the other agent contributes, and the combination can produce a medical emergency.
Beyond serotonergic interactions, RIMAs share the broader MAO-inhibitor concern around sympathomimetics and other agents that potentiate monoamine signaling; the serotonergic drug-interaction risk is the key clinical theme identified across the RIMA pharmacology literature.[3]
The dietary tyramine restriction familiar from classical irreversible MAOIs is substantially lessened — but not eliminated — because rising gut tyramine concentrations can partially displace a RIMA from MAO-A, partially restoring tyramine metabolism.[6] High tyramine loads at high RIMA exposures, especially with concentrated preparations such as Peganum harmala seed, still carry meaningful hypertensive risk.
Acute toxicity in healthy populations using ayahuasca in controlled settings is generally low, and confirmed serotonin syndrome from the brew alone is rare in systematic review.[10] The same review notes that preclinical models of higher-dose harmaline revealed the most safety signals among the harmala alkaloids, supporting the characterization that harmaline-dominant preparations carry a narrower margin than harmine-dominant ones.
Tolerance & dependence
The literature on tolerance specific to plant-derived beta-carboline RIMAs is sparse, but the reversibility of the binding mechanism gives the class a distinctive shape. Enzyme activity recovers within roughly a day of the last dose, so there is no prolonged residual occupancy that would drive a tolerance-mitigation pattern of dose escalation.[7] Ceremonial use patterns characteristically space sessions widely apart, and a sustained-daily dosing pattern is uncommon outside pharmaceutical contexts.
Physical dependence has not been characterized as a clinical concern for the class. RIMAs do not act at the opioid or GABA-A receptor systems associated with the dangerous withdrawal syndromes of other classes, and abrupt-cessation reports from pharmaceutical RIMA use describe mild, flu-like discontinuation symptoms rather than seizures or other life-threatening events.[11]
Recovery
Because RIMA binding is reversible, the pharmacological "hangover" from the class itself is short — enzyme activity restores rapidly once the alkaloids clear, and the multi-week dietary and drug-interaction window required after irreversible MAOIs does not apply. For anyone experiencing distress after a session, or considering discontinuing a sustained-use pattern, a clinician familiar with monoamine-system pharmacology can advise on safe scheduling and on screening for interactions before resuming any serotonergic medication.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1] ^Amrein, R. and Hetzel, W. and Stabl, M. and Schmid-Burgk, W. (1993) RIMA--a new concept in the treatment of depression with moclobemide — International Clinical Psychopharmacology doi:10.1097/00004850-199300730-00001
- [2]
- [3] ^abLotufo-Neto, F. and Trivedi, M. and Thase, M.E. (1999) Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression — Neuropsychopharmacology doi:10.1016/s0893-133x(98)00075-x
- [4] ^abHandforth, A. (2012) Harmaline Tremor: Underlying Mechanisms in a Potential Animal Model of Essential Tremor — Tremor and Other Hyperkinetic Movements doi:10.5334/tohm.108
- [5] ^Herraiz T, Gonzalez D, Ancin-Azpilicueta C, Aran VJ, Guillen H (2010) beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO) — Food and Chemical Toxicology doi:10.1016/j.fct.2009.12.019
- [6] ^abFlockhart, D.A. (2012) Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update — Journal of Clinical Psychiatry doi:10.4088/jcp.11096su1c.03